The AACE guideline of 2023 has included therapy options of either a GLP-1 RA or pioglitazone for patients who have experienced strokes or transient ischemic attacks, and continues to recommend mono, dual, or triple therapy based on HbA1c laboratory values [4, 9]. Here, GCG is linked to stroke disorder.